14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Antiphospholipid Antibody Syndrome: Diffuse Alveolar Hemorrhage and Libman-Sacks Endocarditis in the Absence of Prior Thrombotic Events

      letter
      , MD, FRCPC, , MD, , MD, FRCP(C)
      The Ulster Medical Journal
      The Ulster Medical Society

      Read this article at

      ScienceOpenPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Editor, Antiphospholipid antibody syndrome (APS) is traditionally characterized by the presence of circulating antiphospholipid antibodies (aPL) that lead to an increased risk of thrombosis and pregnancy morbidity.1, 2 Considered rare, diffuse alveolar hemorrhage (DAH) is thought to be a non-thrombotic manifestation of APS, likely secondary to aPL induced pulmonary capillaritis.3 The diagnosis needs to be considered even in the absence of known thrombosis, as multiple recent case reports have identified DAH as the presenting symptom.4 CASE A 35-year-old mother of four from El Salvador presented with a two day history of pronounced dyspnea and hemoptysis. Two years prior she had been diagnosed with adult-onset epilepsy and had undergone mitral valve replacement (MVR) for severe presumed rheumatic mitral stenosis. Pathologic evaluation of the resected valve revealed leaflet fibrosis with Libman-Sacks endocarditis. There was no previous history of thrombosis or pregnancy loss. She was afebrile and was able to speak in full sentences with a SpO2 of 92% on room air. Inspiratory crackles were auscultated bilaterally. No systemic findings of a connective tissue disease were present. CXR demonstrated extensive bilateral air space disease. Computed tomography of the chest identified bilateral groundglass opacities ( Figure 1 ). Fiberoptic bronchoscopy demonstrated no endobronchial source of bleeding. Sequential bronchoalveolar lavage aliquots became progressively more hemorrhagic with microscopic evidence of hemosiderin-laden macrophages, suggesting diffuse alveolar hemorrhage ( Figure 2 ). Laboratory investigations revealed the presence of a non-specific inhibitor, positive anti-cardiolipin IgG antibody, positive anti-dsDNA antibody, and serum thrombocytopenia and lymphopenia. Workup was negative for ANCA or anti-GBM related disease. A probable diagnosis of APS with suspected underlying systemic lupus erythematosus (SLE) was made. The patient underwent induction therapy with pulse-dose corticosteroids and IV cyclophosphamide with rapid clinical and radiographic improvement. Figure 1 CXR completed at time of presentation reveals bilateral airspace disease (a). Coronal CT chest images completed at the same time reveal bilateral, predominantly central, heterogeneous groundglass opacities, involving both upper and lower zones with subpleural sparing (b). These opacities quickly resolved upon treatment with high-dose corticosteroids and IV cyclophosphamide (c). Figure 2 First (left) and second (right) sequential aliquots obtained from bronchoalveolar lavage. Serial returns are progressively hemorrhagic. DISCUSSION APS mediated capillaritis represents a rare cause of DAH.4 Although APS is traditionally defined by strict diagnostic criteria, recent literature supports the pathogenic role of APS in many non-thrombotic disease states.5 Non-criteria manifestations of APL include livedo reticularis, cardiac valve disease, thrombocytopenia, non-thrombotic neurologic manifestations, and nephropathy. Given our patient's thrombocytopenia, recently diagnosed seizure disorder, and positive aPL on two occasions, a diagnosis of probable APS was made. Her valvular disease was not considered diagnostic, as while APS is a known cause of Libman-Sacks endocarditis, it typically causes regurgitant mitral valve lesions rather than stenosis, consistent with the previous diagnosis of rheumatic heart disease. APS may occur as an independent disease entity – primary APS – or in the setting of an underlying disease, usually SLE. In our patient, comorbid SLE is suspected given the presence of anti-dsDNA antibodies, lymphopenia, and recurrent idiopathic seizure. Given the morbidity of DAH, the high-risk of recurrence, and the suspected underlying SLE, the patient has been managed with cyclophosphamide and hydroxychloroquine. Her inflammatory markers have normalized and she has had no subsequent disease flare. Conclusion: DAH can be the presenting manifestation of APS in the absence of traditional manifestations such as venous/arterial thrombosis or pregnancy morbidity.

          Related collections

          Most cited references4

          • Record: found
          • Abstract: found
          • Article: not found

          Antiphospholipid antibodies as a cause of pulmonary capillaritis and diffuse alveolar hemorrhage: a case series and literature review.

          To discuss the clinical manifestations and possible pathogenic mechanisms of the unusual syndrome of diffuse alveolar hemorrhage (DAH) and pulmonary capillaritis without thrombosis in the setting of the primary antiphospholipid antibody syndrome (PAPS). Four men with DAH and capillaritis in the setting of PAPS are identified. Their clinical presentations, laboratory, radiographic, and pathologic findings are reviewed as is their clinical course and response to therapy. In addition, the literature regarding DAH and pulmonary capillaritis in the setting of PAPS is reviewed. The patients presented with dyspnea, hemoptysis, fever, hypoxia, and diffuse alveolar infiltrates; none had evidence of acute thromboembolic disease. All secondary causes of DAH were ruled out. All patients had positive testing for the lupus anticoagulant and high-titer anticardiolipin antibodies, including antibodies against the beta-2-glycoprotein I antigen. Three cases had lung biopsies that revealed pulmonary capillaritis and DAH with no evidence of thrombosis. All patients improved with high-dose corticosteroids. Recurrent disease in the setting of aggressive immunosuppression responded to intravenous immunoglobulin. Antiphospholipid antibody-mediated endothelial cell activation in the absence of thrombosis may induce capillaritis as seen in these cases. The syndrome of DAH and pulmonary capillaritis is further defined. Evidence supports a causative relationship between PAPS, pulmonary capillaritis, and DAH in the absence of thromboembolic disease. Further elucidation of a possible nonthrombotic mechanism of antiphospholipid antibody-mediated pathology is needed to guide future therapies for this unusual manifestation of PAPS.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Non-criteria manifestations of antiphospholipid syndrome.

            Only few studies have addressed the pathogenesis and treatment of the non-criteria manifestations of antiphospholipid antibodies (aPL) such as thrombocytopenia, nephropathy, cardiac valve disease, cognitive dysfunction, skin ulcers, or diffuse pulmonary hemorrhage. There is no consensus on the management of these manifestations; they may occur despite full-dose anticoagulation or may not improve if anticoagulation is initiated after their discovery. This brief review may help physicians in the management of the non-criteria manifestations of aPL.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Diffuse alveolar hemorrhage and Libman-Sacks endocarditis as a manifestation of possible primary antiphospholipid syndrome.

              Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of circulating autoantibodies against phospholipid-binding plasma proteins, leading to an increased risk of thrombosis and pregnancy loss. The most common manifestation of lung disease in APS is pulmonary embolism, which may often be the presenting symptom. We present a 30-year-old man with probable primary APS (with no history of thromboses) presenting with diffuse alveolar hemorrhage, an uncommon presentation. He was also found to have severe mitral valve regurgitation and during valve replacement surgery had cardiac vegetations compatible with a presentation of Libman-Sacks endocarditis. There are only 21 other reported cases of diffuse alveolar hemorrhage occurring as a result of APS. This is the first case of Libman-Sacks endocarditis in the setting of probable APS and alveolar hemorrhage.Diffuse alveolar hemorrhage should be considered as a nonthrombotic manifestation of APS, even in the absence of known thromboses, and may be the presenting symptom.
                Bookmark

                Author and article information

                Contributors
                Role: Fellow in Respiratory Medicine
                Role: Fellow in Rheumatology
                Role: Professor of Medicine
                Journal
                Ulster Med J
                Ulster Med J
                umj
                The Ulster Medical Journal
                The Ulster Medical Society
                0041-6193
                January 2014
                : 83
                : 1
                : 47-49
                Affiliations
                Department of Medicine, McMaster University, Ontario, Canada
                Author notes
                T2127 Firestone Institute for Respiratory Health, St. Joseph's Healthcare, McMaster University, 50 Charlton Ave East, Hamilton, Ontario, L8N 4A6. Canada, Email: amcivor@ 123456stjosham.on.ca , New to Twitter Follow me at @MacCOPD, Like My Facebook Page https://www.facebook.com/MacCopd, Phone: 905 522 1155 Ext 34330, Fax: 905 521 6183
                Article
                3992095
                24757270
                472a91e0-252e-4eb0-a133-345d63e76da0
                © The Ulster Medical Society, 2014
                History
                Categories
                Letters

                Medicine
                Medicine

                Comments

                Comment on this article